Close
Back to mobile site

Bristol-Myers' (BMY) Lack of Suitor Positive for Celgene (CELG) Deal - Baird

March 12, 2019 1:34 PM EDT Send to a Friend
Baird analyst Brian Skorney reiterated an Outperform rating and $101.00 price target on Celgene (NASDAQ: CELG), saying they are positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login